logo
logo

Jupiter Endovascular raised $21M in new financing led by Sonder Capital to fund a pivotal trial for Pulmonary Embolism.

Aug 15, 2024•11 months ago

Amount Raised

$21 Million

Menlo ParkMedical DeviceMedicalBiotechnologyHealth Care

Investors

Sonder Capital

Description

Jupiter Endovascular has exited stealth mode with a $21 million round of financing. The funding will support the company's upcoming pivotal trial for Pulmonary Embolism and further development of its Endoportal ControlTM technology.

Company Information

Company

Jupiter Endovascular

Location

Menlo Park, California, United States

About

Jupiter Endovascular is a medical technology startup developing the “endoportal procedure,” a new class of endovascular interventions using Endoportal Control to bring the precision and control of direct surgical access to catheter-based therapies. The procedure uses an endoportal device that navigates flexibly through the vasculature via percutaneous access. Once in position, the endoportal device can be fixed into a stable state to deliver an interventional treatment with surgical-like precision and control from an endovascular access point.

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Related People